Insider · CIK 0001235598
James M Frates
Files at SAGE (Sage Therapeutics, Inc.), AMLX (Amylyx Pharmaceuticals, Inc.). First filing Apr 2, 2025, latest Sep 14, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AMLX: Amylyx Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 52Moderate | Amylyx Pharmaceuticals, Inc. | $350k 10,810 shares | -4% | +182% from low-19% from high | |
| 43Moderate | Amylyx Pharmaceuticals, Inc. | $38k 10,896 shares | -4% | +42% from low-50% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -9,768 | $32.27 | $315k | 234,667 | 28 d ago |
| Sep 10, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,042 | $33.23 | $35k | 233,625 | 28 d ago |
| Jun 11, 2025 | SAGE Sage Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +21,500 | $0.00 | $0 | 21,500 | Jun 13, 2025 |
| Mar 31, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -10,896 | $3.47 | $38k | 290,988 | Apr 2, 2025 |
| Mar 6, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | AGrant or award Common Stock | +68,420 | $0.00 | $0 | 301,884 | Mar 10, 2025 |
| Mar 6, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +102,630 | $0.00 | $0 | 102,630 | Mar 10, 2025 |
| Jan 3, 2025 | SAGE Sage Therapeutics, Inc. | AGrant or award Stock Options (Right to buy)derivative | +19,154 | $0.00 | $0 | 19,154 | Jan 6, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.